Source comparison
IGF-1 LR3 Muscle Growth Complete Guide 2026: Comparison of Growth Factor Analogs
Researchers evaluating IGF-1 LR3 often compare it to other peptide growth factors used in muscle hypertrophy models. The table below contrasts IGF-1 LR3 with native IGF-1, MK-677 (a growth hormone secretagogue), and mechanical growth factor (MGF), focusing on
This comparison does not assign a generated winner or score.
- Researchers evaluating IGF-1 LR3 often compare it to other peptide growth factors used in muscle hypertrophy models. The table below contrasts IGF-1 LR3 with native IGF-1, MK-677 (a growth hormone secretagogue), and mechanical growth factor (MGF), focusing on half-life, receptor targets, and documented hypertrophy outcomes in published studies.
- IGF-1 LR3
- 20–30 hours
- IGF-1R (muscle, liver)
- 15–25% increase in fiber CSA (rodent models, 4-week protocols)
- Receptor desensitization after 4–6 weeks continuous use
- Best for time-limited hypertrophy studies; requires structured cycles
- Native IGF-1
- <10 minutes
- IGF-1R (sequestered by IGFBPs)
- Minimal direct effect due to rapid clearance
- Binding proteins neutralize >90% before reaching muscle tissue
- Ineffective for sustained anabolic signaling without pharmaceutical modification
- MK-677 (Ibutamoren)
- 24 hours (oral bioavailable)
- Ghrelin receptor (pituitary)
- Indirect: 8–12% increase via GH/IGF-1 axis stimulation
- Elevated cortisol and prolactin in some subjects; water retention
- Useful for GH pulse studies; less direct muscle receptor activation than IGF-1 LR3
- MGF (Mechano Growth Factor)
- 5–7 hours
- IGF-1R (splice variant)
- Localized hypertrophy in mechanically loaded muscle (10–18% fiber growth in targeted areas)
- Short half-life limits systemic effect; requires frequent dosing
- Effective for muscle-specific studies; impractical for whole-body protocols
- IGF-1 LR3 occupies a distinct position: long enough half-life to sustain receptor activation without requiring multiple daily doses, but short enough cycle tolerance to avoid permanent receptor downregulation. MK 677 works through an entirely different pathway. Stimulating endogenous GH pulses rather than directly activating muscle IGF-1 receptors. Making it complementary rather than competitive in research designs that layer growth factor pathways.